Swedish atomic layer deposition technology company Nanexa issued a statement saying that it has reached a pharmaceutical technical cooperation agreement with Novo Nord up to 1,165 billion euros. Novo Nordisk has obtained exclusive global licensing from Nanexa's atomic layer deposition drug delivery technology platform for specific therapeutic peptide drugs, with indications covering obesity and type 2 diabetes. Novo Nordisk will be responsible for the global development and commercialization of this technology. The agreement includes a down payment of €615 million and potential milestone payments. Nanexa said in addition, the agreement also agreed that future product sales would pay royalties at a low single-digit ratio.

Zhitongcaijing · 2d ago
Swedish atomic layer deposition technology company Nanexa issued a statement saying that it has reached a pharmaceutical technical cooperation agreement with Novo Nord up to 1,165 billion euros. Novo Nordisk has obtained exclusive global licensing from Nanexa's atomic layer deposition drug delivery technology platform for specific therapeutic peptide drugs, with indications covering obesity and type 2 diabetes. Novo Nordisk will be responsible for the global development and commercialization of this technology. The agreement includes a down payment of €615 million and potential milestone payments. Nanexa said in addition, the agreement also agreed that future product sales would pay royalties at a low single-digit ratio.